EQT life science
EQT Life Science develops medications, devices, and methods to combat it.
Business Model:
Revenue: $42.9M
Employees: 11-50
Rankings
Industries / Tags:
Detailed EQT life science Information
EQT life science was acquired by
EQT.
The acquisition happend on 2021-11-10.
Details of the transaction were not public
Acquirer
Geographic Data
Address: Johannes Vermeerplein 9
City: Amsterdam
State: noord-holland
Zip: 1071 DV
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
4,837,703Website Global Rank
2,148Website Monthly Traffic
Twitter Followers
Description
EQT life science develops innovative medicines, devices and tools to address the single most important thing that matters to all the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
| 11/2014 | Curetis | Series B | 0 |
| 6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
| 11/2009 | Vivoryon Therapeutics | Series B | 0 |
| 1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
| 10/2021 | DNA Script | Series C | 0 |
| 8/2007 | BioProcessors | Series C | 10M |
| 4/2007 | Affimed | Series B | 32M |
| 12/2018 | XyloCor Therapeutics | Series A | 17M |
| 10/2012 | Affimed | Series D | 20.1M |
| 8/2016 | Rotation Medical | Series B | 12M |
| 7/2014 | Rotation Medical | Series B | 27.2M |
| 1/2021 | Neurent Medical | Series B | 0 |
| 7/2009 | Pasteuria Bioscience | Series B | 0 |
| 12/2009 | Curetis | Series A | 27.9M |
| 2/2019 | Arvelle Therapeutics | Series A | 0 |
| 12/2000 | PamGene | Series A | 6.2M |
| 6/2015 | Neuravi | Series B | 21.5M |
| 3/2021 | XyloCor Therapeutics | Series A | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 10/2021 | OneProjects | Series A | 8M |
| 5/2023 | VarmX | Series B | 0 |
| 1/2012 | Prosensa | Venture Round | 0 |
| 6/2007 | Kiadis Pharma | Venture Round | 0 |
| 2/2018 | Merus | Post-IPO Equity | 55.8M |
| 7/2021 | Xilis | Series A | 0 |
| 12/2021 | AviadoBio | Series A | 0 |
| 7/2020 | ViCentra | Venture Round | 0 |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 1/2017 | Binx Health | Series D | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 12/2015 | Xeltis | Series B | 3.3M |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 3/2015 | Cardiac Dimensions | Equity | 15.2M |
| 9/2018 | Endotronix | Series D | 0 |
| 9/2020 | Cardiac Dimensions | Series C | 17.5M |
| 10/2008 | Cobalt Technologies | Series C | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 8/2021 | T-knife | Series B | 110M |
| 10/2021 | Egle Therapeutics | Series A | 0 |
| 3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
| 5/2017 | ImCheck Therapeutics | Series A | 21.9M |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 7/2014 | Mint Solutions | Series A | 6M |
| 8/2016 | Mint Solutions | Series B | 5.6M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 4/2021 | Onward | Venture Round | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 4/2014 | Binx Health | Series B | 0 |
| 3/2017 | Rainier Therapeutics | Series B | 30M |
| 7/2020 | VarmX | Series B | 36.3M |
| 11/2016 | OxThera | Series D | 34.1M |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 4/2023 | Evommune | Series B | 50M |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 1/2010 | Kreatech Diagnostics | Series B | 0 |
| 1/2016 | Rainier Therapeutics | Series A | 13M |
| 4/2020 | Kiadis Pharma | Post-IPO Equity | 5.5M |
| 6/2011 | Mendor | Series B | 11.7M |
| 1/2016 | ViCentra | Series B | 10.9M |
| 9/2014 | Affimed | Series E | 0 |
| 9/2016 | Immunic Therapeutics | Series A | 19.6M |
| 5/2020 | Arvelle Therapeutics | Series A | 0 |
| 8/2007 | FlowCardia | Series C | 0 |
| 2/2010 | Promethera Biosciences | Series A | 7.3M |
| 11/2011 | Harvest Automation | Series B | 7.9M |
| 11/2003 | Affectis Pharmaceuticals | Series A | - |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 8/2007 | Isto Technologies | Series E | 0 |
| 4/2000 | NewBiotics | Venture Round | 6.3M |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 5/2011 | Cobalt Technologies | Series D | 0 |
| 10/2015 | Luxendo | Series A | 0 |
| 8/2018 | Artios Pharma | Series B | 0 |
| 9/2019 | Pharvaris | Series B | 66M |
| 1/2011 | Nexstim | Venture Round | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 1/2009 | BMEYE | Series A | - |
| 5/2019 | DNA Script | Series B | 38.5M |
| 7/2020 | Cybin | Series B | 0 |
| 3/2014 | Hybrigenics | Post-IPO Equity | 8.4M |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 4/2004 | NewBiotics | Series E | 4.6M |
| 5/2016 | Nouscom | Series A | 13.6M |
| 11/2017 | Xeltis | Series C | 53M |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 5/2008 | Asoyia | Venture Round | 4M |
| 2/2022 | Perfuze | Series A | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 3/2010 | Seahorse Bioscience | Series D | 5M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 8/2021 | Visus Therapeutics | Equity | 20M |
| 6/2020 | OneProjects | Series A | 12.4M |
| 1/2010 | Harvest Automation | Series A | 4M |
| 4/2014 | Heart Metabolics | Series A | 20M |
| 1/2007 | 4-Antibody AG | Series A | 18.4M |
| 10/2012 | Cobalt Technologies | Venture Round | 5M |
| 3/2019 | SNIPR Biome | Series A | 50M |
| 12/2014 | Xeltis | Series B | 33.5M |
| 4/2005 | DNage | Series A | 1.9M |
| 1/2016 | Pharvaris | Series A | 16.3M |
| 4/2006 | Pronota | Series A | 7.8M |
| 1/2010 | Merus | Series B | 0 |
| 4/2012 | Cobalt Technologies | Venture Round | 2.9M |
| 1/2005 | OctoPlus | Series B | 23.9M |
| 5/2018 | Rainier Therapeutics | Series B | 20M |
| 2/2007 | Prosensa | Series A | 18M |
| 9/2010 | Harvest Automation | Series A | 1.3M |
| 10/2013 | Harvest Automation | Series C | 11.8M |
| 5/2003 | Santarus | Series D | 51.4M |
| 7/2017 | Simplify Medical | Series B | 21M |
| 2/2018 | Simplify Medical | Series B | 23M |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2009 | Kreatech Diagnostics | Venture Round | 0 |
| 10/2007 | Hyperion Therapeutics | Debt Financing | 15M |
| 9/2007 | Nexstim | Venture Round | 10.9M |
| 4/2016 | Onward | Series A | 29.5M |
| 10/1999 | Devgen | Series B | 24.7M |
| 1/2012 | Pronota | Series C | 4.8M |
| 1/2007 | Movetis | Series A | 63.8M |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 2/2009 | ActoGeniX | Private Equity Round | 17.4M |
| 2/2007 | ActoGeniX | Venture Round | 26.1M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
| 11/2012 | Kiadis Pharma | Venture Round | 0 |
| 7/2001 | NewBiotics | Series C | 0 |
| 9/2016 | Vivasure Medical | Series C | 18.3M |
| 9/2017 | Immunic Therapeutics | Series A | 11.9M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 12/2006 | BMEYE | Series A | - |
| 7/2020 | DNA Script | Series B | 50M |
| 7/2002 | Scion Pharmaceuticals | Series B | 0 |
| 7/2003 | PamGene | Series B | 11.3M |
| 8/2006 | Pronota | Series A | 10.6M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 4/2023 | Evommune | Series B | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 2/2022 | Perfuze | Series A | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 12/2021 | AviadoBio | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
